Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(Cell 165, 35–44; March 24, 2016) We have updated the online version of our paper to include the accession numbers to the patient-derived whole exome datasets that were not available at the time of publication. The datasets can be accessed at the Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra) under the accession numbers SRA: SRP067938 (UCLA samples) and SRA: SRP090294 (UCLA and Vanderbilt samples). Table S1 has also been updated to include the reference to the SRA run IDs. We apologize for any inconvenience that this delay may have caused. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaHugo et al.CellMarch 17, 2016In BriefHigh mutational loads are associated with improved survival in melanoma patients but are not predictive of response to anti-PD-1 therapy, suggesting that other genomic and non-genomic features also contribute to response patterns on PD-1 checkpoint blockade therapy. Full-Text PDF Open Archive